Objective: The aim of this study was to determine whether older postmenopausal women with a history of bilateral oophorectomy before natural menopause (surgical menopause) have a higher risk of nonvertebral postmenopausal fracture than women with natural menopause.
A mong women of reproductive age in the United States, hysterectomy is the second most frequently performed surgical procedure after cesarean delivery. About 20 million US women have had a hysterectomy, and about 600,000 hysterectomies are performed annually. 1 According to recent estimates, nearly 40% of women aged 15 to 44 years who undergo hysterectomy also have bilateral oophorectomy. 1, 2 Although several studies have suggested an association between early menopause and decreased bone mineral density (BMD) and an increased risk of osteoporosis, 3 no prospective cohort studies have assessed the impact of surgical menopause on long-term fracture risk. Therefore, we investigated whether women who underwent premenopausal bilateral oophorectomy (surgical menopause) were at an increased risk of nonvertebral fracture compared with women who experienced natural menopause. We further evaluated whether the observed associations of these surgeries with fracture risk were modified through postmenopausal oral estrogen therapy. We hypothesized that older women with a history of surgical menopause would have a higher risk of nonvertebral fracture than those without surgical menopause, and that this risk would be diminished through the use of oral estrogen.
METHODS
We evaluated the effects of premenopausal bilateral oophorectomy (with or without hysterectomy) before menopause on fracture risk in comparison with natural menopause using data collected through August 2007 from the ongoing Study of Osteoporotic Fractures (SOF). SOF is a multicenter prospective study of risk factors for fracture in 9,704 communitydwelling white women 65 years older enrolled into the cohort from 1986 to 1988. 4 Women were recruited irrespective of their BMD status or fracture history and were excluded only if they had undergone bilateral hip replacement or were unable to walk without the help of another person. All women provided written informed consent and the institutional review boards at each site approved this study.
The participants were asked at baseline to provide their age at the time of their last natural menstrual period and at the time of oophorectomy and/or hysterectomy, if applicable. Participants were asked whether they still had menses after their hysterectomy to confirm hysterectomy status. From this information, we defined four menopausal groups: (1) menopause resulting from premenopausal bilateral oophorectomy (surgical menopause, n = 1,157) with or without hysterectomy; (2) premenopausal hysterectomy without simultaneous bilateral oophorectomy (n = 1,679), which included women with no ovaries removed, one ovary removed, uncertainty about ovarian status, or bilateral oophorectomy performed at a later date; (3) natural menopause with a history of oophorectomy or hysterectomy (n = 1,288); and (4) natural menopause without previous oophorectomy or hysterectomy (n = 5,459, referent). We excluded women who could not confirm whether their hysterectomy occurred before or after menstrual cessation (n = 1), who did not know whether they had had a hysterectomy (n = 18), or who did not provide any information about menopause (n = 102) from the analyses. Evaluation of fracture risk among women with postmenopausal oophorectomy in this cohort has previously been performed, and no increased risk of fracture was found. 5 Therefore, for this analysis, we excluded women with natural menopause who had postmenopausal hysterectomy or oophorectomy. Because the time of menopause could not be ascertained for women without bilateral oophorectomy at the time of hysterectomy, this group was also excluded from the primary analyses, yielding a final cohort for analysis of 6,616 women with surgical or natural menopause.
The primary fractures of interest for this study were incident hip, wrist, and any nontraumatic nonvertebral fracture. Fractures resulting from major trauma were excluded. Study participants have been contacted by mail or telephone every 4 months to identify the occurrence of fractures (more than 95% complete to date). Incident fractures were verified by physician review of radiology reports.
Information was collected from all participants at baseline by questionnaire, review of medication bottles, food intake diaries, and physical examination. The baseline characteristics of primary interest included age at baseline and menopause, calcium and alcohol intake, tobacco use, obstetrical history (parity and breastfeeding), medical history (diabetes, self-reported health, fracture since age of 50 y, and height at age 25 y), maternal history of fracture, medications (oral estrogen and long-acting benzodiazepines), activity level (evaluated as time spent on feet during the day), and physical measures (pulse, weight, depth perception, contrast sensitivity, and BMD). These characteristics were chosen because they have been associated with fracture risk. 4, 6, 7 BMD measurements of the distal radius and calcaneus were performed at baseline through single-photon absorptiometry using Osteo-Analyzers (Siemens-Osteon, Wahiawa, HI), whereas ascertainment of BMD of the proximal femur using dual energy x-ray absorptiometry (DXA; QDR 1000; Hologic, Waltham, MA) was first performed at the second study visit, between 1988 and 1990, for the 8,074 women surviving at that time. Age at menopause was considered unknown or missing for women who experienced natural menopause but could not recall their age when it occurred (n = 77). All covariates included in the multivariate models were from the baseline examination, except for oral estrogen use. Estrogen use was updated about every 2 years at each study visit, and these data were used to determine continuous use or nonuse of oral estrogen for each participant.
Statistical analyses
t tests for continuous variables and Pearson W 2 tests for categorical variables were used to assess differences in baseline characteristics between menopause groups. Cox proportional hazards regression models were used to estimate the risk of fracture (hazard ratio [HR], 95% CI). Time to fracture was defined as the time from baseline to the first hip, wrist, or nonvertebral fracture. Women who did not have a fracture or died before a fracture were censored at the time of death or at the time of their last available follow-up questionnaire.
Recently published data suggest that traumatic fractures should also be included as outcomes in observational studies. 8 Given our decision to exclude women with traumatic fractures, we performed a sensitivity analysis including women in the SOF cohort who had traumatic fractures, and the results were unchanged.
Multivariable regression models were developed to provide relative risk estimates of fracture. The models were stratified by estrogen use because there was a significant interaction between menopause type and estrogen use status. For analyses among never and past users of oral estrogen, those who began using estrogen during follow-up were censored at the time they first reported estrogen use (including 28 never users with hip fracture, 21 with wrist fracture, and 78 with any nonvertebral fracture and 37 past users with hip fracture, 27 with wrist fracture, and 91 with any nonvertebral fracture). For analyses among current users of estrogen, those who discontinued estrogen use were censored at the time they reported that they stopped taking this medication (including 38 women with hip fracture, 18 with wrist fracture, and 99 with any nonvertebral fracture). Women with missing estrogen data at a specific study visit were assigned the same status as at their previous visit.
The stratified models were then adjusted for all characteristics that differed significantly between the two menopause groups. To determine the impact of BMD on the relationship between menopause and fracture, BMD was added last to the multivariable models, and the results are reported separately. Because DXA was not performed until the second SOF clinic visit, we used baseline BMD measures for the models (calcaneal BMD for hip and any nonvertebral fracture models and distal radius for wrist fracture models). Previous studies among the SOF cohort have demonstrated that appendicular bone density measures are strong predictors of nonvertebral fractures. 9, 10 All P values were based on two-sided tests of significance and a P value less than 0.05 was considered statistically sig-nificant for our analyses. Statistical analyses were performed using SAS software version 8.2 (SAS Institute Inc, Cary, NC).
RESULTS
The baseline characteristics of the 6,616 women included in the analysis varied considerably by menopause type, and those that differed significantly are shown in Table 1 . Women with a history of surgical menopause were younger at enrollment (70.8 vs 71.7 y, P G 0.001), weighed more (67.8 vs 66.7 kg, P = 0.01), and had a higher mean calcium intake (2,942 mg/wk vs 2,640 mg/wk, P = 0.03). Among women with a history of surgical menopause, 62.2% were current or past users of oral estrogen, which was about twice that of women with natural menopause (31.7%, P G 0.001). Therefore, it is not surprising that women with a history of surgical menopause also had higher mean BMD measures at all sites (P G 0.001, Table 1 ). Only 0.15% (n = 14) reported ever using an estrogen patch. Menopause groups did not differ in parity, activity levels (evaluated as e4 h on feet daily), maternal history of hip fracture, personal history of fracture since age 50 years, height at age 25 years, and pulse or in smoking status (current, past, or never); however, the mean pack-year history among current or past smokers was higher for the surgical menopause group (12.5 vs 10.7 pack-years, P = 0.01).
During a mean follow-up of 14.3 years (SD, 5.4 y; range, 0.02-20.6 y), 2,697 nontraumatic, nonvertebral fractures were identified, of which there were 909 hip and 669 wrist fractures. Age-adjusted incidence rates of fracture for the whole cohort and stratified by estrogen use status are shown in Table 2 . The incidence rates differed between the two menopause groups and between estrogen use strata.
Women who underwent surgical menopause had a lower incidence of hip fracture (13.6 vs 16.5 fractures per 1,000 person-years, P G 0.05) and a higher incidence of wrist (9.3 vs 7.8 per 1,000, P G 0.05) and any nonvertebral fracture (54.2 vs 50.3 per 1,000, P G 0.05) compared with women with natural menopause. When stratified by estrogen use status, the ageadjusted incidence rates of fracture were generally highest among women who had never used estrogen and were lowest among current estrogen users. Among women who never used oral estrogen, the age-adjusted incidence rates of hip fracture were lower (14.2 vs 16.4 per 1,000, P G 0.05), but the rates of wrist (10.3 vs 7.6 per 1,000, P G 0.05) and any nonvertebral fracture (61.4 vs 48.9 per 1,000, P G 0.05) were higher for women with surgical menopause compared with those with natural menopause. Among current users of estrogen, women with surgical menopause had lower incidence rates of hip, wrist, and any nonvertebral fracture (P G 0.05). We then evaluated fracture risk in multivariable models (Tables 3-5) .
Among women with no history of oral estrogen use, the risks of hip (HR, 0.87; 95% CI, 0.63-1.21), wrist (HR, 1.08; 95% CI, 0.76-1.54), and any nonvertebral fracture (HR, 1.10; 95% CI, 0.92-1.31) did not differ in multivariable models, even when adjusted for BMD (Table 3) .
Among past users of oral estrogen, risks of hip (HR, 0.94; 95% CI, 0.63-1.41) and wrist fracture (HR, 0.78; 95% CI, 0.50-1.23) did not differ significantly in multivariable models or multivariable models adjusted for BMD (Table 4 ). There was a lower risk of any nonvertebral fracture for women with surgical menopause that bordered on statistical significance (HR, 0.79; 95% CI, 0.63-0.99), but this was not significant when adjusted for BMD (HR, 0.81; 95% CI, 0.64-1.02), although the direction of the hazard ratio was the same.
Among current users of oral estrogen, women with surgical menopause had a lower rate of hip (HR, 0.38; 95% CI, 0.16-0.90) and nonvertebral fracture (HR, 0.63; 95% CI, 0.43-0.92), but not wrist fracture (HR, 0.56; 95% CI, 0.21-1.51; Table 5 ). When BMD was added to the models, these relationships were not statistically significant.
DISCUSSION
Contrary to our hypothesis, we did not observe an increased risk of any fracture type for surgical compared with natural menopause, even when taking history of estrogen use into consideration. The relative risks for hip and wrist fracture identified in our prospective SOF cohort of nearly 10,000 women mirror those found in the retrospective study of 463 women in Olmstead County, MN, which is the only other longitudinal study to evaluate surgical menopause and fracture risk among older women. In that cohort, 463 women (187 with no estrogen exposure) with premenopausal bilateral oophorectomy had no increased risk of hip fracture compared with women in their community, but did have a modest (although not significantly) increased risk of distal forearm fracture. 11 In the Olmstead county cohort, a nonsignificant trend to the increased risk of fracture with earlier onset (per 10-y decrease in age) of estrogen deficiency was identified. However, a subanalysis performed among estrogen users found that the increasing duration of estrogen therapy was not protective for distal forearm or hip fractures.
Whether or not surgical menopause increases the risk of vertebral (spine) fracture is also an important consideration; however, incident vertebral fractures are more difficult than nonvertebral fractures to identify. In contrast with nonvertebral fractures, only about one third of vertebral fractures are clinically recognized. 12 In SOF, prevalent vertebral fractures were identified using lateral thoracic and lumbar spine x-rays at baseline. Incident vertebral fractures were ascertained at the year 16 visit, when follow-up radiographs were performed. An incident fracture was defined as 20% or higher and 4 mm or more decrease in vertebral height at any level 13 when compared with the initial radiograph. Because the assessment for incident vertebral fracture required that women survive until the year 16 visit, only a subset of the original cohort underwent a second radiograph. Unadjusted analyses indicate that the cumulative risk of vertebral fracture was lower for women with surgical (27 of 279, 9.7%) compared with those with natural menopause (210 of 1,295, 16.2%; P G 0.006). Given the small numbers of vertebral fractures, statistical power would be low for a complete analysis stratified by estrogen use status. Nonetheless, these results are consistent with the nonvertebral fracture findings in this cohort.
Patterns of trabecular and cortical bone loss may provide a biological explanation for the lack of increased risk of fracture among women with surgical compared with those with natural menopause. In young adults, before the onset of bone loss, the vertebrae, distal radius, and femoral neck are composed predominantly of trabecular bone. 14 Data from quantitative CT have shown that trabecular bone loss in women seems to begin in the third decade, well in advance of the onset of estrogen deficiency. 14, 15 Although trabecular bone loss seems to accelerate slightly with the menopausal transition, continued loss wanes among older women. 14, 15 In contrast, cortical bone loss seems to either begin or accelerate in midlife (around the time of menopause) and decline in a linear manner. 14 Studies conducted among older postmenopausal women have shown that femoral and lumbar spine BMD measures (assessed using DXA) do not differ between women with bilateral oophorectomy and intact ovaries. 16, 17 Furthermore, a prospective study among older postmenopausal women that carefully controlled for estrogen therapy demonstrated that total hip, femoral neck, and lumbar spine bone loss among women with bilateral oophorectomy or with only hysterectomy was no greater than bone loss among naturally menopausal women. 17 Within our study, mean total hip, calcaneal, and distal radius bone mineral density measures were significantly higher for women who underwent surgical compared with natural menopause, probably because of the fact that more women in the surgical menopause group were current users of estrogen. Among women in SOF who had never used oral estrogen, these BMD measures did not differ significantly between the two menopause groups (data not shown). The lack of significant difference in BMD may explain why there was not a higher risk of fracture among women with surgical menopause (compared with natural menopause) and, moreover, why the addition of BMD as a covariate in multivariable models stratified by, and adjusted for, duration of estrogen use did not change the results.
It is possible that recall might affect the ability of women to accurately report their menopause status or the age at which they underwent hysterectomy, oophorectomy, or menopause. Validation of menopause type was not performed in the SOF cohort because it was shown to be accurately reported in other cohorts. 18, 19 In general, self-report of surgery agrees very well with medical records (J 9 0.9). 19 In the Rancho Bernardo cohort of women aged 60 to 89 years who had characteristics (mean age, 74 y; primarily white and educated) similar to the SOF cohort, the oophorectomy status of a subsample of women who had undergone hysterectomy was validated against medical records. 18 Self-reported bilateral oophorectomy was confirmed by medical records in 96% of cases; validity was less if oophorectomy was not bilateral. 18 To minimize misclassification bias in our study, we classified women as surgical menopause only if premenopausal bilateral oophorectomy was reported. Moreover, we performed a subanalysis for excluded women with uncertain oophorectomy status and confirmed that these results were similar to those included as surgical menopause (data not shown). These data provide reassurance that random misclassification of ovarian status is an improbable explanation for the lack of association of menopause type and fracture risk. Fracture outcome misclassification is also improbable in this study because fracture reports were adjudicated without the knowledge of menopause status.
Because this is a study of primarily white women, it is not generalizable to women of other races. However, white women have a higher risk of fracture than do other races or ethnicities, and they account for the greatest amount of health resource utilization related to osteoporotic fracture. Finally, although subgroup analyses may have limited power to detect significant differences, we did find statistical differences in the comparisons among current estrogen users (the group with the smallest sample size and the fewest number of events). Therefore, we do not believe that subgroup analyses are underpowered. Furthermore, it is reassuring that the hazard ratios are less than 1.0 for all fracture types among both past and current estrogen users and for hip fracture among never users. If the differences in wrist and any nonvertebral fracture were statistically significant among never users, then, in clinically meaningful terms, premenopausal bilateral oophorectomy would result in five additional nonvertebral fractures per 1,000 person-years of observation and less than one additional wrist fracture per 1,000 person-years for women with surgical compared with natural menopause.
This study has many strengths. SOF is the first large prospective cohort study to evaluate whether surgical menopause increases the risk of nonvertebral fracture. It is also the first study to provide prospectively assessed, stratified nonvertebral fracture rates for practitioners to use when counseling women at the time of hysterectomy or after natural menopause. In addition, the SOF cohort provides an unparalleled opportunity with the large numbers of women unexposed to oral estrogen therapy after menopause (more than 50% of the cohort) to evaluate fracture risk among women without estrogen exposure for more than 2 decades since menopause.
Our findings are important to help inform decision making among premenopausal women preparing to undergo hysterectomy. Many studies in the United States and Europe have documented changes in attitudes toward estrogen therapy and have demonstrated a decline in hormone therapy use and prescribing since the results of the Women's Health Initiative were published. 20<22 It is also possible that fewer women in the coming years will choose to use oral estrogen therapy after surgical menopause. Epidemiological studies suggest that premature menopause (surgical or natural) without estrogen therapy is associated with an increased risk of heart disease and decreased long-term survival. 23, 24 Other potential risks to consider at the time of oophorectomy are the potential for decreased libido if the ovaries are removed and the risk of repeat surgery for ovarian pathology if the ovaries are retained. 25 Moreover, because one of the primary reasons for bilateral oophorectomy is ovarian cancer prophylaxis, women must weigh the risk of fracture against the risk of ovarian cancer, which, in a lifetime for women at average risk, is about 1.4%. 26 It is important to note that although there is no accurate screening test for ovarian cancer and the harms of screening for it in average-risk women outweigh the benefits, 27 the assessment of bone density is predictive of fracture risk in postmenopausal women and, therefore, screening for osteoporosis is recommended for all women 65 years and older. 28 Furthermore, there is an effective treatment of osteoporosis and methods for the prevention of osteoporotic fracture. 29, 30 
CONCLUSIONS
This study is the first to prospectively assess the risk of fracture associated with surgical menopause and provides some reassurance that the long-term risk of nonvertebral fracture is not substantially increased for postmenopausal women who experienced surgical menopause, even in the absence of postmenopausal estrogen therapy. Our risk estimates are similar to those reported by a good-quality, retrospective cohort study, 11 giving credence to their use in the clinical setting. The lack of increased hip fracture risk among women who underwent surgical menopause (compared with natural) is reassuring given that surgical menopause is common 1 and that hip fractures are associated with the greatest morbidity, mortality, and public health burden of any fracture type. 31, 32 
